NYSE:ABT - Abbott Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$71.49 +0.07 (+0.10 %)
(As of 01/22/2019 04:00 PM ET)
Previous Close$71.42
Today's Range$70.69 - $71.67
52-Week Range$55.58 - $74.92
Volume6.54 million shs
Average Volume7.57 million shs
Market Capitalization$125.56 billion
P/E Ratio28.60
Dividend Yield1.82%
Beta1.24
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.39 billion
Cash Flow$4.7916 per share
Book Value$17.87 per share

Profitability

Net Income$477 million

Miscellaneous

Employees99,000
Outstanding Shares1,756,333,000
Market Cap$125.56 billion
OptionableOptionable

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, December 14th. Investors of record on Tuesday, January 15th will be paid a dividend of $0.32 per share on Friday, February 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.79%. The ex-dividend date is Monday, January 14th. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.28. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, October, 17th. The healthcare product maker reported $0.75 earnings per share for the quarter, meeting the consensus estimate of $0.75. The healthcare product maker earned $7.66 billion during the quarter, compared to analyst estimates of $7.65 billion. Abbott Laboratories had a net margin of 2.91% and a return on equity of 16.05%. The firm's revenue for the quarter was up 12.1% compared to the same quarter last year. During the same period last year, the company earned $0.66 EPS. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Abbott Laboratories.

How can I listen to Abbott Laboratories' earnings call?

Abbott Laboratories will be holding an earnings conference call on Wednesday, January 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for ABT?

21 brokers have issued twelve-month price objectives for Abbott Laboratories' stock. Their forecasts range from $68.00 to $86.00. On average, they anticipate Abbott Laboratories' share price to reach $76.8474 in the next year. This suggests a possible upside of 7.5% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

What is the consensus analysts' recommendation for Abbott Laboratories?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 3 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

Media coverage about ABT stock has trended very positive this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news headlines about the healthcare product maker a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White, Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 40)

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include Atalanta Sosnoff Capital LLC (0.06%), Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%), Park National Corp OH (0.03%) and Gofen & Glossberg LLC IL (0.03%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which major investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Sit Investment Associates Inc., Dalton Greiner Hartman Maher & Co., Gulf International Bank UK Ltd, Gradient Investments LLC, Stralem & Co. Inc., Prentiss Smith & Co. Inc. and Nisa Investment Advisors LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which major investors are buying Abbott Laboratories stock?

ABT stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Patten & Patten Inc. TN, Gillespie Robinson & Grimm Inc., Centre Asset Management LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, Cullinan Associates Inc., Nachman Norwood & Parrott Inc and MinichMacGregor Wealth Management LLC. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $71.49.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $125.56 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  715 (Vote Outperform)
Underperform Votes:  577 (Vote Underperform)
Total Votes:  1,292
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel